Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | GALR3 | O60755 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23779934 | 0.81 | TSHR (0.37) | TSHRALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL23779935 | 0.81 | TSHR (0.37) | TSHRALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL31163977 | 0.78 | TSHR (0.39) | TSHRALDH1A1TP53 | |
| SCHEMBL10892018 | 0.78 | TSHR (0.39) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL13326291 | 0.78 | TSHR (0.39) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL7593773 | 0.78 | TSHR (0.34) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL5355975 | 0.78 | ALDH1A1 (0.39) | TSHRALDH1A1TP53 | |
| SCHEMBL5355970 | 0.78 | ALDH1A1 (0.39) | TSHRALDH1A1TP53 | |
| SCHEMBL6468395 | 0.77 | TSHR (0.31) | TSHR | |
| SCHEMBL8989063 | 0.77 | TSHR (0.47) | TSHRALDH1A1TP53CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855302-B2 | Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino-3.5-dihydroxyhepanoic acid derivatives and intermediates thereof | CIBA SPECIALTY CHEMICALS CORP. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7692034-B2 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-04-06 | — | — | US | disclosed |
| EP-2161250-A1 | Process for the preparatiom of 7-amino-syn-3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | BASF SE (DE) | 2010-03-10 | — | — | EP | disclosed |
| EP-1404642-B1 | Process for the preparatiom of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | BASF SE (DE) | 2010-02-17 | — | — | EP | disclosed |
| US-7504532-B2 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-17 | — | — | US | disclosed |
| US-20080312466-A1 | Synthesis and intermediates | OHRLEIN REINHOLD | 2008-12-18 | — | — | US | disclosed |
| US-7420078-B2 | Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3,5-dihydroxy heptanoic acid derivatives, and intermediates thereof | CIBA SPECIALTY CHEMICALS CORP. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080125601-A1 | PROCESS FOR THE PREPARATION OF 7-AMINO SYN 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, INTERMEDIATES THEREOF AND METHODS FOR THEIR PREPARATION | BASF SE (DE) | 2008-05-29 | — | — | US | disclosed |
| US-7317123-B2 | Process for preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | TEVA PHARMACEUTICAL INDUSTRIES, LTD (IL) | 2008-01-08 | — | — | US | disclosed |
| US-7199261-B2 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2007-04-03 | — | — | US | disclosed |
| US-20050033086-A1 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | BASF SE (DE) | 2005-02-10 | — | — | US | disclosed |
| US-20040242916-A1 | Process for preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | BASF SE (DE) | 2004-12-02 | — | — | US | disclosed |
| US-20040186313-A1 | Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3 5-dihydroxy heptanoic acid derivatives, and intermediates thereof | CIBA SPECIALTY CHEMICALS CORP. | 2004-09-23 | — | — | US | disclosed |
| EP-1406860-A1 | PROCESS FOR THE PREPARATION OF 7-AMINO SYN 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES VIA 6-CYANO SYN 3,5-DIHYDROXY HEXANOIC ACID DERIVATIVES | Teva Pharmaceutical Industries Limited (IL) | 2004-04-14 | — | — | EP | disclosed |
| EP-1404639-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES ESPECIALLY 7-AMINO 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, AND INTERMEDIATES THEREOF | Ciba SC Holding AG (CH) | 2004-04-07 | — | — | EP | disclosed |
| EP-1404642-A2 | SYNTHESIS AND INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003004455-A2 | PROCESS FOR THE PREPARATION OF 7-AMINO SYN 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, INTERMEDIATES THEREOF AND METHODS FOR THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-01-16 | — | — | WO | disclosed |
| WO-2003004450-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES ESPECIALLY 7-AMINO 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, AND INTERMEDIATES THEREOF | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-01-16 | — | — | WO | disclosed |
| WO-2003004456-A1 | PROCESS FOR THE PREPARATION OF 7-AMINO SYN 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES VIA 6-CYANO SYN 3,5-DIHYDROXY HEXANOIC ACID DERIVATIVES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186313-A1 | Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3 5-dihydroxy heptanoic acid derivatives, and intermediates thereof | HMGCR, CYP46A1, CYP7A1 | TSHR 4204/4885ALDH1A1 490/4885TP53 4355/4885 |
| US-20080312466-A1 | Synthesis and intermediates | HMGCR, SREBF1, COASY | TSHR 3067/4885ALDH1A1 1326/4885TP53 3559/4885 |
| US-20080125601-A1 | PROCESS FOR THE PREPARATION OF 7-AMINO SYN 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, INTERMEDIATES THEREOF AND METHODS FOR THEIR PREPARATION | HMGCR, DHCR7, CYP8B1 | TSHR 3246/4885ALDH1A1 2063/4885TP53 1892/4885 |
| US-20050033086-A1 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | HMGCR, DHCR7, HCAR3 | TSHR 2793/4885ALDH1A1 2430/4885TP53 2729/4885 |
| US-20040242916-A1 | Process for preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | HMGCR, DHCR7, CYP8B1 | TSHR 3525/4885ALDH1A1 2643/4885TP53 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.